Telomir Pharmaceuticals (TELO) Assets Average (2024 - 2026)
Telomir Pharmaceuticals (TELO) posted Assets Average of $7.4 million for Q4 2025, up 79.11% sequentially from $4.1 million in Q3 2025, and up 523.14% YoY from $1.2 million in Q4 2024.
Telomir Pharmaceuticals (TELO) Assets Average (2024 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Assets Average for 2 years, with the latest figure at $7.4 million in Q4 2025.
- Quarterly Assets Average rose 523.14% year-over-year to $7.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.4 million (up 523.14% YoY) and the FY2025 annual result came in at $4.3 million, up 42.11% from the prior year.
- Assets Average grew to $7.4 million in Q4 2025 per TELO's latest filing, from $4.1 million in the prior quarter.
- Over five years, Assets Average peaked at $7.4 million in Q4 2025 and troughed at $660399.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 19.82 Bn |
| 10 | Telomir Pharmaceuticals | 68.47 Mn | 68.47 Mn | - | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.35 Mn |
| Dec 31, 2025 | 7.37 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Jun 30, 2025 | 660,399.50 |
| Mar 31, 2025 | 907,596.50 |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 4.14 Mn |